<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/">
<rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/3773">
    <dcterms:title><![CDATA[<strong>Streamlined method for parallel identification of single domain antibodies to membrane receptors on whole cells</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[RECEPTOR DE LA CELULA]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2015]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Background<br /><br />Owing to their minimal size, high production yield, versatility and robustness, the recombinant variable domains (nanobodies) of camelid single chain antibodies are valued affinity reagents for research, diagnostic, and therapeutic applications. While their preparation against purified antigens is straightforward, the generation of nanobodies to difficult targets such as multi-pass or complex membrane cell receptors remains challenging. Here we devised a platform for high throughput identification of nanobodies to cell receptor based on the use of a biotin handle.<br />Methods<br /><br />Using a biotin-acceptor peptide tag, the in vivo biotinylation of nanobodies in 96 well culture blocks was optimized allowing their parallel analysis by flow cytometry and ELISA, and their direct use for pull-down/MS target identification.<br />Results<br /><br />The potential of this strategy was demonstrated by the selection and characterization of panels of nanobodies to Mac-1 (CD11b/CD18), MHC II and the mouse Ly-5 leukocyte common antigen (CD45) receptors, from a VHH library obtained from a llama immunized with mouse bone marrow derived dendritic cells. By on and off switching of the addition of biotin, the method also allowed the epitope binning of the selected Nbs directly on cells.<br />Conclusions<br /><br />This strategy streamlines the selection of potent nanobodies to complex antigens, and the selected nanobodies constitute ready-to-use biotinylated reagents.<br />General significance<br /><br />This method will accelerate the discovery of nanobodies to cell membrane receptors which comprise the largest group of drug and analytical targets.<br /><br />]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Rossotti, Mart&iacute;n</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Tabares, Sof&iacute;a</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Alfaya, Luc&iacute;a</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Leizagoyen, Carmen</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Moron, Gabriel</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<a title="Curriculum Vitae" href="http://buscadores.anii.org.uy/buscador_sni/exportador/ExportarPdf?hash=7ee0def1187be47e0710e877d9768b5a" target="_blank"><strong>Gonz&aacute;lez-Sapienza, Gualberto G.</strong></a>]]></dcterms:creator>
    <dcterms:source><![CDATA[Biochimica et Biophysica Acta v. 1850, no. 7, 2015. -- p. 1397-1404]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2015]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong><br /> <br /> (Por favor lea este aviso antes de abrir los documentos u objetos)<br /> <br /> <strong>La legislaci&oacute;n uruguaya</strong> protege el derecho de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes<br /> <br /> (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)<br /> <br /> <strong>ADVERTENCIA -</strong> La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[doi:10.1016/j.bbagen.2015.03.009]]></dcterms:identifier>
</rdf:Description></rdf:RDF>
